Application of TNF (Tumor Necrosis Factor) alpha neutralizing antibody and IFN (Interferon) gamma neutralizing antibody in preparation of medicine for preventing and treating trichloroethylene immune renal injury
Through the combined treatment of TNFα neutralizing antibody and IFNγ neutralizing antibody, the problem of lag in renal function improvement in rh TNFR:Fc treatment was solved, which significantly promoted the recovery of liver and renal function in patients with occupational trichloroethylene drug erection dermatitis and improved treatment Effect.
Patent Information
- Application Number
- CN202411238710.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The renal function improvement in patients with occupational trichloroethylene drug erection dermatitis (OMDT) is lagging behind in the treatment of renal function in patients with recombinant human type II tumor necrosis factor receptor-antibody fusion protein (rh TNFR:Fc) and affects the treatment effect.
Combination of TNFα neutralizing antibody and IFNγ neutralizing antibody is used to promote early recovery of liver and renal function in OMDT patients.
By inhibiting the CFH expression of renal vascular endothelial cells, the combination of TNFα neutralizing antibodies and IFNγ neutralizing antibodies significantly promoted the recovery of TCE immune renal injury and improved the therapeutic effect.
Smart Images

Figure HDA0005028537450000011 
Figure HDA0005028537450000012 
Figure HDA0005028537450000021
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of clinical medicine, and in particular to the application of TNFα neutralizing antibody and IFNγ neutralizing antibody in the preparation of medicines for preventing and treating trichloroethylene immune kidney damage. Background Art
[0002] As an important chemical raw material, trichloroethylene (TCE) is widely used in metal cleaning, dry cleaning of clothes, production of biopharmaceuticals, pesticides, adhesives, etc. In recent years, it has been used as a raw material for the production of green refrigerant hydrofluorocarbons, which has led to an increase in the use of TCE in my country year by year, reaching 102,500 tons in 2020. After some people are exposed to TCE, they may develop a systemic immune disease characterized by large-area skin and mucous membrane damage, often accompanied by fever, systemic lymphadenopathy, and severe liver and kidney damage, etc. This disease is called occupational medicamentosa-like dermatitis induced by trichloroethylene (OMDT).
[0003] High-dose glucocorticoid therapy is still the main treatment for OMDT patients, but this therapy has disadvantages such as long hospitalization time and many complications, which often brings great physical, psychological and economic pressure to patients and their families, which is a difficulty in clinical treatment in the field of occupational health. Therefore, it is urgent to seek precise treatment methods for OMDT, and it is of great occupational health significance to explore the pathogenesis of OMDT and find new targets. The incidence of immune liver and kidney damage in OMDT patients is extremely high, and most deaths of patients are caused by liver and kidney failure. The degree of liver and kidney damage is closely related to the patient's course and prognosis. Therefore, during clinical treatment, it is necessary to focus on the patient's liver and kidney function.
[0004] After occupational sensitization to TCE, the immune system is activated and can produce a variety of pro-inflammatory factors to participate in the body's immune response. However, overactivation of the immune system can lead to the appearance of inflammatory cytokine storms and damage the body. The significant increase in circulating tumor necrosis factor alpha (TNFα) is a characteristic clinical manifestation of inflammatory cytokine storms in patients with various types of dermatitis OMDT. In addition, clinical studies have found that in addition to the significant increase in TNFα in the blood circulation of OMDT patients, especially patients with severe skin lesions such as exfoliative dermatitis and bullous epidermal necrolysis, there is also an abnormal increase in interferon-gamma (IFNγ), and its expression level is several times or even dozens of times higher than that of the control group (Li Hongling, Zhu Chunying, Zhao Na, et al. Analysis of the dynamic changes in cytokine levels in patients with occupational trichloroethylene drug eruption dermatitis [J] .Chinese Journal of Occupational Medicine. 2020; 47(06): 705-710.; Zhu Chunying, Zhao Na, Li Hongling, et al. Correlation between cytokine levels and liver function damage in patients with trichloroethylene drug eruption-like dermatitis [J]. Chinese Journal of Occupational Medicine. 2020; 47(02): 162-167.; Yi Juan, Liu Zhengyu, Li Tiandi, et al. Analysis of cytokine levels in patients with trichloroethylene drug eruption-like dermatitis [J]. Occupational Health and Emergency Rescue. 2015; 33(02): 89-91.). TNFα has a direct cytotoxic effect on target cells, can promote the expression of adhesion molecules by vascular endothelial cells, and can attract macrophages to aggravate the inflammatory response. Giving TCE-sensitized mice TNFα receptor inhibitors can partially alleviate liver and kidney damage. Recombinant human type II tumor necrosis factor receptor-antibody fusion protein (rhTNFR:Fc) has also begun to be used in the clinic to treat OMDT. The regimen uses rhTNFR: Fc 25mg, subcutaneous injection, twice a week, doubled for the first time, a total of 12 injections, the first 8 completed during hospitalization (hospitalization for 4 weeks), and the last 4 completed during the follow-up period. At the same time, compound glycyrrhizic acid injection is used for liver protection treatment, fluid therapy is strengthened, water and acid-base balance, plasma support, etc., and skin and mucosal care are strengthened to prevent and treat infection and other symptomatic treatments. After treatment, it was found that the patient's liver function improved rapidly within one week after treatment, while the patient's renal function did not improve significantly after one week of treatment, and did not improve until 2 weeks of treatment, and returned to normal in 4 weeks (Lv Lingling. Efficacy of recombinant human type II tumor necrosis factor receptor-antibody fusion protein in the treatment of severe occupational trichloroethylene drug eruption dermatitis [D]. Suzhou University, 2016.).
[0005] Clinical application of recombinant human type II tumor necrosis factor receptor-antibody fusion protein (rh TNFR:Fc) in the treatment of occupational trichloroethylene drug eruption dermatitis (OMDT) patients, after early application, the patient's liver function improved rapidly, but the improvement of renal function lagged behind, which affected the treatment effect to a certain extent. Therefore, the problem of poor effect of rh TNFR:Fc in the treatment of OMDT renal injury needs to be solved urgently. Summary of the invention
[0006] The purpose of the present invention is to provide the use of TNFα neutralizing antibodies and IFNγ neutralizing antibodies in the preparation of drugs for preventing and treating trichloroethylene immune renal injury, so as to solve the problems existing in the above-mentioned prior art. The present invention uses TNFα neutralizing antibodies and IFNγ neutralizing antibodies for combined treatment to promote the rapid recovery of liver and kidney function in the early stage of OMDT patients, so as to further improve the prognosis.
[0007] To achieve the above object, the present invention provides the following solutions:
[0008] One of the technical solutions of the present invention is the use of TNFα neutralizing antibody and IFNγ neutralizing antibody in the preparation of medicine for preventing and treating trichloroethylene immune renal injury.
[0009] The second technical solution of the present invention is a drug for preventing and treating trichloroethylene immune renal injury, comprising TNFα neutralizing antibody and IFNγ neutralizing antibody.
[0010] The third technical solution of the present invention is the use of TNFα neutralizing antibodies and IFNγ neutralizing antibodies in the preparation of drugs for preventing and treating occupational trichloroethylene drug eruption-like dermatitis.
[0011] A fourth technical solution of the present invention is a drug for preventing and treating occupational trichloroethylene drug eruption-like dermatitis, comprising a TNFα neutralizing antibody and an IFNγ neutralizing antibody.
[0012] Based on the above technical solution, the present invention has the following technical effects:
[0013] The present invention found that TNFα combined with IFNγ inhibits the expression of CFH in renal vascular endothelial cells. CFH promotes the expression of adhesion molecules in endothelial cells and inhibits the expression of glycocalyx proteins and intercellular junction proteins in endothelial cells, destroys the renal endothelial barrier function, and participates in TCE immune renal injury. Compared with the treatment with TNFα neutralizing antibody or IFNγ neutralizing antibody alone, the combined use of TNFα neutralizing antibody and IFNγ neutralizing antibody can significantly promote the recovery of TCE immune renal injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0015] Figure 1 Figure 2 The relationship between TNFα and IFNγ levels and renal injury in patients with OMDT. The levels of peripheral blood TNFα(a), IFN-γ(b), Cre(c), BUN(d), peripheral blood Cys-c(e) and urine β2-MG(f) in patients with OMDT were significantly higher than those in the control group (P<0.05). Linear regression analysis showed that TNFα was positively correlated with Cre(P<0.01)(g), and nearly positively correlated with BUN(P=0.0508)(h) and Cys-c(P=0.0559)(i), but had no significant correlation with β2-MG(P=0.5361)(j). IFNγ was positively correlated with Cre(P<0.01)(k) and Cys-c(P<0.05)(m), and nearly positively correlated with β2MG(P=0.099)(n), but had no correlation with BUN(P=0.5597)(l). Multiple linear regression showed that the synergistic effect of TNFα and IFN-γ was positively correlated with Cre (P<0.01) (o) and Cys-c (P<0.05) (q), but not with BUN (P=0.142) (p) or β2MG (P=0.302) (r). *P<0.05, **P<0.01.
[0016] Figure 2 Figure 2 The relationship between TNFα and IFNγ levels and ECs damage in patients with OMDT. The levels of peripheral ET-1 (a), urinary ET-1 (b), and urinary VCAM1 (c) in patients with OMDT were significantly higher than those in the control group (P<0.05). Linear regression analysis showed that TNFα was positively correlated with peripheral ET-1 (P<0.05) (d), but not with urinary ET-1 (P=0.2078) (e) or urinary VCAM1 (P=0.2546) (f). IFNγ was positively correlated with peripheral blood ET-1 (P<0.05) (g), urinary ET-1 (P<0.05) (h), and urinary VCAM1 (P<0.05) (i). Multiple linear regression showed that the synergistic effect of TNFα and IFN-γ was positively correlated with peripheral blood ET-1 (P<0.01)(j) and urine VCAM1 (P<0.05)(l), and was almost positively correlated with urine ET-1 (P=0.087)(k). *P<0.05, **P<0.01.
[0017] Figure 3The expression of CFH in mouse and human renal glomerular endothelial cells (HRGECs). Among them, the immunofluorescence results of CFH in mouse kidney tissue (a); the immunohistochemistry results of mouse kidney tissue (b); TNFα combined with IFNγ treatment of HRGECs significantly inhibited CFH expression (c); TNFα combined with IFNγ treatment of HRGECs CFH immunofluorescence results (d).
[0018] Figure 4 The results show that the neutralization of peripheral blood TNFα and IFNγ inhibited the activation of renal ECs. Among them, the flow cytometry results of the number of peripheral blood CECs (a). The number of CECs in each group (b). Neutralization of peripheral blood TNFα and IFNγ inhibited the level of urinary ET1 (c). Neutralization of peripheral blood TNFα and IFNγ inhibited the level of urinary VCAM1 (d). Neutralization of peripheral blood TNFα and IFNγ inhibited the expression of ICAM1 and VCAM1 in mouse kidney tissue (e). Neutralization of peripheral blood TNFα and IFNγ restored the expression of glypican1 and syndecan1 in mouse kidney tissue (f). Neutralization of peripheral blood TNFα and IFNγ inhibited the expression of VE-cadherin and occludin in mouse kidney tissue (g). ns indicates not significant; *P<0.05.
[0019] Figure 5 Neutralization of peripheral blood TNFα and IFNγ alleviates renal injury caused by trichloroethylene sensitization. Simultaneous application of TNFα neutralizing antibody and IFNγ neutralizing antibody can reduce the levels of blood TNFα (a), IFNγ (b), Cre (c), BUN (d) and Cys-c (e) and the levels of urine α1MG (f) and β2MG (g). Among them, HE staining results (scale bar, 50 μm) (h), PAS staining results (scale bar, 50 μm) (i). TEM results of glomerular ECs and tubular ECs (j). *p<0.05, **p<0.01.
[0020] Figure 6It is a key protein for CFH to regulate the damage of human renal glomerular endothelial cells (HRGECs) induced by TNFα and IFNγ. Among them, a is the result of treating HRGECs with small interfering RNA to affect its CFH protein expression. b is the WB result of ICAM1 and VCAM1 after interfering with CFH expression in HRGECs. c is the result of the concentration of ICAM1 in the cell culture supernatant after interfering with CFH expression in HRGECs. d is the result of the concentration of VCAM1 in the cell culture supernatant after interfering with CFH expression in HRGECs. e is the result of transfecting HRGECs with overexpression plasmid to affect its CFH protein expression. f is the WB result of ICAM1 and VCAM1 after overexpressing CFH expression in HRGECs. g is the result of the concentration of ICAM1 in the cell culture supernatant after overexpressing CFH expression in HRGECs. h is the result of the concentration of VCAM1 in the cell culture supernatant after overexpressing CFH expression in HRGECs. i is the WB result of glypican1 and syndecan1 after interfering with CFH expression in HRGECs. j is the WB result of VE-cadherin and occludin after interfering with CFH expression in HRGECs. k is the WB result of glypican1 and syndecan1 after overexpressing CFH expression in HRGECs. l is the WB result of VE-cadherin and occludin after overexpressing CFH expression in HRGECs. m is the result of endothelial cell resistance level detected after interfering with CFH expression in HRGECs. n is the result of endothelial cell resistance level detected after overexpressing CFH expression in HRGECs. ns indicates not significant; *P<0.05; **P<0.01. DETAILED DESCRIPTION
[0021] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0022] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0023] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0024] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.
[0025] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0026] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or have been disclosed.
[0027] The embodiment of the present invention provides the use of TNFα neutralizing antibody and IFNγ neutralizing antibody in the preparation of a drug for preventing and treating trichloroethylene immune renal injury.
[0028] The embodiment of the present invention also provides a medicine for preventing and treating trichloroethylene immune renal injury, comprising a TNFα neutralizing antibody and an IFNγ neutralizing antibody.
[0029] In some specific embodiments, a pharmaceutically acceptable excipient is also included.
[0030] The embodiment of the present invention also provides the use of TNFα neutralizing antibody and IFNγ neutralizing antibody in the preparation of a drug for preventing and treating occupational trichloroethylene drug eruption-like dermatitis.
[0031] The embodiment of the present invention also provides a drug for preventing and treating occupational trichloroethylene drug eruption-like dermatitis, comprising a TNFα neutralizing antibody and an IFNγ neutralizing antibody.
[0032] In some specific embodiments, a pharmaceutically acceptable excipient is also included.
[0033] Example 1
[0034] 1. Case and control population
[0035] From January 2016 to January 2020, a total of 17 OMDT patients aged 15-49 years (11 males and 6 females) were recruited from Guangdong Provincial Institute of Occupational Disease Prevention and Treatment and Shenzhen Occupational Disease Prevention and Treatment Center. Plasma from all patients and urine from 7 patients were collected upon admission. The present invention also recruited 21 control subjects, aged between 18 and 49 years.
[0036] The inclusion criteria for patients were as follows: a clear history of occupational exposure to TCE and newly diagnosed with OMDT according to GBZ 185-2006 “Diagnostic Criteria for Occupational Diseases”.
[0037] Exclusion criteria: age over 60 years old, liver and kidney diseases before exposure to TCE, mental illness, chronic diseases and other serious organic diseases.
[0038] The present invention followed the Code of Ethics of the World Medical Association (Declaration of Helsinki) for human experiments and obtained research ethics approval from the First Affiliated Hospital of Anhui Medical University, ethics approval number: 2023010. Informed consent was obtained for all population studies.
[0039] 2. Patient renal function test
[0040] Blood urea nitrogen (BUN) and creatinine (Cre) levels were measured using an automated biochemical analyzer. Plasma cystatin C (Cys-c) and urine β2-microglobulin (β2-MG) were measured using an enzyme-linked immunosorbent assay (ELISA) to assess glomerular filtration rate and tubular reabsorption function, respectively. The assays were performed according to the manufacturer's instructions.
[0041] 3. Detection of TNFα and IFNγ in patients’ peripheral blood
[0042] The levels of TNFα and IFNγ in peripheral blood were detected by ELISA according to the instructions.
[0043] 4. Detection of renal vascular endothelial cell damage in patients
[0044] Endothelin-1 (ET-1) in peripheral blood and urine and vascular endothelial cell adhesion molecule-1 (VCAM-1) in urine were detected by ELISA to indirectly reflect the damage of renal ECs. The detection method was carried out according to the instructions.
[0045] 5. Establishment of TCE-sensitized mouse model and neutralizing antibody intervention method
[0046] Forty pathogen-free BALB / c female mice (7-8 weeks old) were purchased from Anhui Provincial Experimental Animal Center. The mice were housed in a pathogen-free room with a 12-h / 12-h light / dark cycle and fed normal food. The mice were randomly divided into a blank control group (5 replicates), a solvent control group (5 replicates), a TCE-treated group (15 replicates), and a TCE+TNFα-neutralizing antibody+IFNγ-neutralizing antibody-treated group (15 replicates).
[0047] Before the first exposure to TCE, 2×2 cm2 of hair on the back was shaved. On the first day of modeling (the first time TCE was used), 100 μL of TCE mixture (Freund's complete adjuvant: trichloroethylene: olive oil: acetone = 10:5:2:3) was subcutaneously injected into the back of mice in the TCE treatment group and TCE+TNFα neutralizing antibody + IFNγ neutralizing antibody treatment group. On the 4th, 7th and 10th days, 100 μL of 50% TCE (TCE: olive oil: acetone = 5:2:3) was applied to the back skin of all mice. On the 17th and 19th days, 30% TCE (TCE: olive oil: acetone = 3:2:5) was applied to the back hair of mice. Mice in the TCE+TNFα neutralization + IFNγ neutralization treatment group were injected with 2.5 mg / kg TNFα neutralizing antibody and 2.5 mg / kg IFNγ neutralizing antibody by tail vein on days 15, 17 and 19.
[0048] The mice in the solvent control group were treated with acetone and olive oil in the same volume ratio as those in the TCE-treated group.
[0049] Mice in the blank control group did not receive any treatment.
[0050] On the 20th day, all mice were further divided into sensitized positive mice (skin reaction score ≥ 1) or sensitized negative mice (skin reaction score 0) according to the skin reaction. Results The sensitization rates of the blank control group, solvent control group, and PBS control group were all 0. The sensitization rates of the TCE-treated group were 33.3%, and those of the TCE+TNFα neutralizing antibody+IFNγ neutralizing antibody-treated group were 26.7%. After the scoring, all mice were killed, and 24-hour urine, peripheral blood, kidneys, or renal vascular endothelial cells were collected.
[0051] All animal experiments were performed in accordance with the ARRIVE guidelines and in accordance with the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals and applicable Animal Welfare Act. Animal experiments were approved by Anhui Medical University (Ethics Approval Number: LLSC 20230343).
[0052] 6. Mouse Kidney Injury Detection
[0053] Periodic acid Schiff staining (PAS staining) and hematoxylin and eosin staining (HE staining) were used to evaluate the pathological changes of the kidney. 3 μm paraffin sections were dewaxed, hydrated, stained with corresponding reagents, and the pathological changes were observed under an optical microscope.
[0054] Serum BUN, Cre, Cys-c and urine β2-MG were tested to reflect glomerular filtration and tubular reabsorption functions, respectively. The operation steps were carried out according to the instructions.
[0055] 7. Detection of TNFα and IFNγ in human and mouse peripheral blood
[0056] ELISA was used to detect the levels of TNFα and IFNγ in human and mouse peripheral blood. The detection process was carried out according to the instructions.
[0057] 8. Mouse Renal Vascular Endothelial Cell Injury Detection
[0058] Transmission electron microscopy (TEM) was used to observe the microstructure of renal vascular endothelial cells. Briefly, the renal cortex was fixed in glutaraldehyde and 1% osmotic acid solution. The tissue was then transferred to an aqueous uranyl acetate solution and dehydrated with gradient acetic acid. After routine dehydration, embedding, heating, polymerization, and staining, the structures of glomerular vascular endothelial cells and peritubular capillary endothelial cells were observed.
[0059] The levels of ET-1 and VCAM-1 in urine were detected to reflect the damage of renal vascular endothelial cells. The operation steps were carried out according to the instructions.
[0060] 9. Detection of circulating endothelial cells (CECs) in mouse peripheral blood
[0061] Mouse peripheral blood was collected using EDTA anticoagulant tubes. The tubes were then divided into test tubes, blank test tubes, CD146-PE labeled tubes, and CD45-FITC labeled tubes. All test tubes were injected with 1 ml of blood. Then, the test tubes were incubated with 1 μL CD146-PE antibody and 1 μL CD45-FITC antibody for 20 minutes, the CD146-PE labeled tubes were incubated with 1 μL CD146-PE antibody for 20 minutes, and the CD45-FITC labeled tubes were incubated with 1 μL CD45-FITC antibody for 20 minutes. Then, all test tubes were placed in 3 mL of red blood cell lysis buffer and incubated for 8 minutes, followed by centrifugation at 1500 r / min for 7 minutes. Finally, the supernatant was discarded, the cells were resuspended in sterile PBS, and detected by flow cytometry. CD146+CD45- cells were defined as CECs cells.
[0062] 10. Immunofluorescence
[0063] Co-expression of interferon regulatory factor 1 (IRF1) and CD31 and complement factor H (CFH) and CD31 was detected by immunofluorescence. Paraffin sections of 3 μm thickness were dewaxed, hydrated, treated with 0.3% Triton-100, and then incubated with anti-IRF1 or anti-CFH and anti-CD31 antibodies at 4°C overnight. Finally, the sections were incubated with secondary antibodies and DAPI, and the immunobinding products were observed by fluorescence microscopy.
[0064] 11. Immunohistochemistry
[0065] 3 μm thick paraffin sections were dewaxed, hydrated, and then placed in citric acid for antigen retrieval. They were then blocked with goat serum and incubated with antibodies overnight at 4°C. The next day, the sections were incubated with secondary antibodies, horseradish peroxidase, and DAB staining was used to visualize the antigen-antibody complex.
[0066] 12. Isolation of Mouse Kidney ECs
[0067] Mouse kidney ECs were isolated using magnetic beads. First, magnetic beads were incubated with anti-CD31 antibody overnight and then washed with sterile PBS. Second, mice were perfused via the left ventricle with 10 ml of sterile PBS, followed by 10 ml of PBS containing 100 μl of magnetic beads. The kidneys were collected and then digested with trypsin and type I collagenase, followed by adsorption on a magnetic rack, washing, and collecting the cells.
[0068] 13.Western blot
[0069] Total protein of renal ECs or HRGECs was extracted with RIPA buffer. Protein concentration was determined using a BCA kit. Proteins were then separated by SDS-PAGE. Proteins were then transferred to a PVDF membrane. Primary and secondary antibodies were incubated after milk blocking. Enhanced chemiluminescence was used to detect the signal. The grayscale values of the bands were analyzed using Image J.
[0070] 14. Cell Culture
[0071] HRGECs were cultured in ECM containing 10% FBS, 1% endothelial cell growth supplement (ECGS) and 1% penicillin / streptomycin at 37°C in a humidified environment containing 5% CO2. Lipofectamine 2000 was used to transfect si-RNA, and Lipofectamine 3000 was used to transfect CFH overexpression plasmid. The transfection steps were performed according to the instructions.
[0072] The sequences of each si-RNA are as follows:
[0073] CFH: Forward,5'-GCACAUGGGACUAAAUUGATT-3';
[0074] Reverse,5'-UCAAUUUAGUCCCAUGUGCTT-3'.
[0075] NC: Forward,5'-UUCUCCGAACGUGUCACGUTT-3';
[0076] Reverse,5'-ACGUGACACGUUCGGAGAATT-3'.
[0077] 15. TEER detection
[0078] Endothelial cells were inoculated into transwell chambers, transfected and cultured for 48 hours to allow cell fusion, and then the endothelial resistance of cells was measured every 6 hours using an endothelial resistance meter. When the resistance was stable, it indicated that the cells had formed a stable barrier. At this time, TNFα and IFNγ were used to treat the cells, and the endothelial resistance values were measured and recorded at 0h, 6h, 12h, 24h, and 48h.
[0079] 16. Statistical Analysis
[0080] SPSS V.23.0 and RV.4.2.2 were used for statistical analysis. Data were expressed as mean ± standard deviation (M ± SD). One-way analysis of variance (ANOVA) and least significant difference (LSD) were used to test the differences between the groups. In the present invention, P < 0.05 was considered statistically significant. The relationship between TNFα or IFNγ and ET-1, Cys-c, VCAM-1, β2-MG, BUN, and Cre. The relationship between TNFα and IFN-γ and ET-1, Cys-c, VCAM-1, β2-MG, BUN, and Cre was tested by multiple linear regression analysis.
[0081] 17. Results Analysis
[0082] 17.1 The present invention first verified the relationship between the blood TNFα and IFNγ levels and renal injury in OMDT patients, and found that the peripheral blood TNFα (86.83±9.78pg / ml) and IFNγ (163.93±48.57pg / ml) levels of OMDT patients were significantly higher than those of the control group (TNFα was 22.10±4.05pg / ml, IFNγ was 9.94±1.39pg / ml) ( Figure 1The levels of Cre in blood (74.13±5.28μmol / l), BUN (6.72±0.36mmol / l), peripheral Cys-c (2068.07±278.00ng / ml) and β2MG in urine (360.43±99.73ng / ml) were also higher than those in the control group (Cre: 57.58±2.74μmol / l, BUN: 4.14±0.23mmol / l, Cys-c: 595.10±99.76ng / ml, β2MG: 38.61±2.84ng / ml) ( Figure 1 cf). Linear regression models were then used to analyze the relationship between TNFα and Cre, BUN, Cys-c, and β2MG, and the relationship between IFNγ and Cre, BUN, Cys-c, and β2MG. TNFα was positively correlated with Cre (R 2 =0.3476, P < 0.01), and BUN (R 2 =0.2311, P=0.0508) and Cys-c (R 2 =0.2225, P = 0.0559) is close to positive correlation ( Figure 1 gi), but had no significant correlation with β2MG (R 2 =0.08103, P = 0.5361)( Figure 1 (j) IFNγ and Cre (R 2 =0.4547, P<0.01)( Figure 1 k) and Cys-c(R 2 =0.3098, P<0.05)( Figure 1 m) and is positively correlated with β2MG (R 2 =0.4501, P=0.099)( Figure 1 n), but no significant correlation with BUN (R 2 =0.02318, P = 0.5597)( Figure 1 In addition, the present invention also constructed a multiple linear regression model to analyze the synergistic relationship between TNFα and IFN-γ and Cre, BUN, Cys-c and β2-MG. The results showed that the synergistic effect of TNFα and IFN-γ was related to Cre (R 2 =0.612, P<0.01)( Figure 1 o) and Cys-c(R 2 =0.356, P<0.05)( Figure 1 There was a positive correlation between BUN (R 2 =0.244, P=0.142)( Figure 1 p) and β2-MG (R 2=0.451, P=0.302)( Figure 1 No significant correlation was found in r).
[0083] 17.2 The relationship between TNFα and IFNγ levels and vascular endothelial cell damage in OMDT patients was further tested, and peripheral blood ET-1, urine ET-1 and VCAM-1 were detected to reflect renal ECs damage. The results showed that the levels of peripheral blood ET-1 (38.44±6.45pg / ml), urine ET-1 (3.63±0.47pg / ml) and VCAM-1 (8.08±1.18pg / mL) in patients were significantly higher than those in the control group (peripheral blood ET-1 was 9.25±1.53pg / mL, urine ET-1 was 1.67±0.06pg / mL, and urine VCAM-1 was 2.59±0.23pg / mL) ( Figure 2 The linear regression model showed that TNFα was positively correlated with peripheral blood ET-1 (R 2 =0.4047, P < 0.01), but no correlation was found with urine ET-1 or VCAM-1 ( Figure 2 IFNγ and peripheral blood ET-1 (R 2 =0.5616, P<0.01), urine ET-1(R 2 =0.6416, P < 0.05) and urinary VCAM-1 (R 2 =0.7468, P < 0.05) was positively correlated ( Figure 2 The relationship between TNFα and IFNγ, peripheral ET-1 and urinary ET-1 and VCAM-1 was analyzed by multivariate linear regression model. The results showed that the synergistic effect of TNFα and IFN-γ was related to the expression of peripheral blood ET-1 (R 2 =0.646, P < 0.01) and urinary VCAM-1 (R 2 =0.778, P < 0.05) was positively correlated ( Figure 2 j and k), and was positively correlated with urinary ET-1 (R 2 =0.705, P=0.087)( Figure 2 (middle l).
[0084] 17.3 In order to prove the effect of TNFα combined with IFNγ on renal vascular endothelial cells, the present invention firstly used immunofluorescence ( Figure 3 The localization of CFH in endothelial cells was performed by immunohistochemistry, and it was found that CFH was mainly localized in the endothelial cells of the kidney, and the expression of CFH in endothelial cells in the TCE-sensitized positive group was significantly inhibited. Culturing HRGECs and stimulating the cells with TNFα and IFN-γ confirmed that the expression of CFH in cells was significantly inhibited ( Figure 3 (c) and (d) in 3.
[0085] 17.4 Flow cytometry results showed that compared with the TCE sensitization group, injection of TNFα neutralizing antibody and IFNγ neutralizing antibody could reduce the number of CECs. Injection of TNFα neutralizing antibody and IFNγ neutralizing antibody could reduce the number of CECs to normal level ( Figure 4 After using TNFα neutralizing antibody combined with IFNγ neutralizing antibody, the levels of ET1 and VCAM1 in mouse urine also decreased significantly ( Figure 4 (c and d).
[0086] Endothelial cells were isolated and the protein levels of endothelial cells in each group were quantitatively detected by WB. It was found that after the use of TNFα neutralizing antibody combined with IFNγ neutralizing antibody, the expression levels of chemokines ICAM1 and VCAM1 in mouse kidney endothelial cells were significantly decreased ( Figure 4 e), while the expression levels of cell surface glycocalyx proteins glypican1 and syndecan1 increased significantly ( Figure 4 f), the levels of intercellular junction proteins VE-cadherin and occludin also increased significantly ( Figure 4 (g).
[0087] 17.5 Further testing of mouse renal function and other related indicators revealed that, compared with the TCE sensitization group, injection of TNFα neutralizing antibody and IFNγ neutralizing antibody reduced the levels of TNFα and IFNγ in the peripheral blood of mice ( Figure 5 a and b), the renal function indexes Cre and BUN were significantly decreased ( Figure 5 c and d), the glomerular injury index Cys-c decreased significantly ( Figure 5 e), the renal tubular injury indicators α1MG and β2MG also decreased significantly ( Figure 5 f and g). The PAS staining results and HE results of mouse kidney tissue also found that the injection of TNFα neutralizing antibody and IFNγ neutralizing antibody can reduce the renal damage of mice ( Figure 5 h and i). Transmission electron microscopy also showed that the combined use of TNFα neutralizing antibodies and IFNγ neutralizing antibodies could reduce the damage of mouse kidney endothelial cells ( Figure 5 (j).
[0088] 17.6 Further, the present invention uses small interfering RNA and overexpression plasmid to transfect HRGECs to downregulate or overexpress the CFH protein level of HRGECs. The results show that after successfully inhibiting or overexpressing the CFH gene of HRGECs, the CFH expression level also significantly affects the expression of glycocalyx proteins glypican1 and syndecan1, as well as the levels of intercellular junction proteins VE-cadherin and occludin ( Figure 3Endothelial resistance was measured using a resistor meter to determine the effect of CFH on barrier function. The results also showed that TNFα and IFNγ treatment of HRGECs significantly reduced endothelial resistance and CFH levels, but overexpression of CFH could increase endothelial resistance and endothelial barrier function to a certain extent ( Figure 6 m and n).
[0089] In summary, the present invention found that TNFα combined with IFNγ inhibits the expression of CFH in renal vascular endothelial cells. CFH promotes the expression of adhesion molecules in endothelial cells and inhibits the expression of glycocalyx proteins and intercellular junction proteins in endothelial cells, ultimately destroying the renal endothelial barrier function and participating in TCE immune renal injury. Compared with the treatment with TNFα neutralizing antibody or IFNγ neutralizing antibody alone, the combined use of TNFα neutralizing antibody and IFNγ neutralizing antibody can significantly promote the recovery of TCE immune renal injury.
[0090] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. Application of TNFα neutralizing antibody and IFNγ neutralizing antibody in the preparation of drugs for preventing and treating trichloroethylene immune renal injury.
2. A drug for preventing and treating trichloroethylene immune renal injury, characterized in that: Including TNFα neutralizing antibodies and IFNγ neutralizing antibodies.
3. The drug according to claim 2, characterized in that Pharmaceutically acceptable excipients are also included.
4. Application of TNFα neutralizing antibody and IFNγ neutralizing antibody in the preparation of drugs for preventing and treating occupational trichloroethylene drug eruption dermatitis.
5. A drug for preventing and treating occupational trichloroethylene drug eruption-like dermatitis, characterized in that: Including TNFα neutralizing antibodies and IFNγ neutralizing antibodies.
6. The drug according to claim 5, characterized in that Pharmaceutically acceptable excipients are also included.
Citation Information
Patent Citations
Methods and compositions for improved tissue regeneration by suppression of interferon -gamma and tumor necrosis factor-alpha
CN103619177A
Methods for treating or modulating an inflammatory response
US20240018230A1
